Results 191 to 200 of about 2,335,195 (317)

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

Arthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

Per‐ and polyfluoroalkyl substances and hand osteoarthritis: data from the Osteoarthritis Initiative

Arthritis &Rheumatology, Accepted Article.
Objective To explore whether biological levels of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS – reflecting the overall effect and accounting for correlations among each PFAS – relate to incident hand osteoarthritis (HOA) and progression.
Jeffrey B. Driban, Lisa B. Rokoff, Bing Lu, Timothy E. McAlindon, Charles B. Eaton, Mary B. Roberts, Diana Mathes, Colleen Lestician, Zhijin Carrie Xu, Zhihua Tina Fan, Shawn P. O'Leary, Ida K. Haugen, Jérémie Sellam, Alice Courties, Abby F. Fleisch   +14 more
wiley   +1 more source

Rehabilitation of patients with stroke: summary of SIGN guidance [PDF]

, 2010
Barber, M., Chung, C., Gillespie, D., James, R., Ramsay, S., Smith, L.N.   +5 more
core   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using national Veterans Health Administration (VHA), Medicare, and National Death Index data (2006‐2020).
Tate M. Johnson, Halie Frideres, Punyasha Roul, Joshua F. Baker, Brian C. Sauer, Grant W. Cannon, Isaac D. Smith, Gary A. Kunkel, Beth I. Wallace, Thomas R. Porter, Kaveh R. Bookani, Amarnath R. Annapureddy, Ted R. Mikuls, Bryant R. England   +13 more
wiley   +1 more source

GWAS and Replication Analysis of Apparent Treatment-Resistant Hypertension. [PDF]

Hypertension
Ebinger JE, Kauko A, Vaura F, Hage P, Sundström J, FinnGen, Joung SY, Cheng S, Niiranen TJ.   +8 more
europepmc   +1 more source

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Amiloride: revisiting an old drug for resistant hypertension. [PDF]

Clin Hypertens
Lee CJ, Park S.
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source